MX2020004155A - Uso de pirrolidonas heteroaromaticas fusionadas para el tratamiento y prevencion de enfermedades en animales. - Google Patents

Uso de pirrolidonas heteroaromaticas fusionadas para el tratamiento y prevencion de enfermedades en animales.

Info

Publication number
MX2020004155A
MX2020004155A MX2020004155A MX2020004155A MX2020004155A MX 2020004155 A MX2020004155 A MX 2020004155A MX 2020004155 A MX2020004155 A MX 2020004155A MX 2020004155 A MX2020004155 A MX 2020004155A MX 2020004155 A MX2020004155 A MX 2020004155A
Authority
MX
Mexico
Prior art keywords
animals
treatment
diseases
prevention
fused heteroaromatic
Prior art date
Application number
MX2020004155A
Other languages
English (en)
Inventor
Ulf Bömer
Nils Griebenow
Gerald Beddies
Iring Heisler
Maria De Lourdes Mottier
Jörg Cramer
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of MX2020004155A publication Critical patent/MX2020004155A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere al uso de pirrolidonas heteroaromáticas fusionadas para el tratamiento y/o la profilaxis de enfermedades alérgicas y/o inflamatorias en los animales y se refiere a su uso para la producción de medicamentos para el tratamiento y/o profilaxis de enfermedades alérgicas y/o inflamatorias en los animales, especialmente de la dermatitis atópica y/o de la dermatitis alérgica por picadura de pulga, y especialmente en animales domésticos, particularmente en los perros.
MX2020004155A 2017-10-19 2018-10-15 Uso de pirrolidonas heteroaromaticas fusionadas para el tratamiento y prevencion de enfermedades en animales. MX2020004155A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17197344 2017-10-19
PCT/EP2018/078086 WO2019076817A1 (en) 2017-10-19 2018-10-15 USE OF FUSED HETEROAROMATIC PYRROLIDONES FOR THE TREATMENT AND PREVENTION OF DISEASES IN ANIMALS

Publications (1)

Publication Number Publication Date
MX2020004155A true MX2020004155A (es) 2020-08-03

Family

ID=60143623

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004155A MX2020004155A (es) 2017-10-19 2018-10-15 Uso de pirrolidonas heteroaromaticas fusionadas para el tratamiento y prevencion de enfermedades en animales.

Country Status (18)

Country Link
US (1) US11077111B2 (es)
EP (1) EP3665171A1 (es)
JP (1) JP2020537678A (es)
KR (1) KR20200073216A (es)
CN (1) CN111194319A (es)
AU (1) AU2018350683A1 (es)
BR (1) BR112020007679A2 (es)
CA (1) CA3079292A1 (es)
CL (1) CL2020001036A1 (es)
DO (1) DOP2020000093A (es)
IL (1) IL273834A (es)
MX (1) MX2020004155A (es)
PH (1) PH12020550444A1 (es)
RU (1) RU2020116178A (es)
SG (1) SG11202002475TA (es)
TW (1) TW201922744A (es)
UY (1) UY37945A (es)
WO (1) WO2019076817A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE288420T1 (de) 1999-06-09 2005-02-15 Yamanouchi Pharma Co Ltd Neuartige heterocyclische carboxamid-derivate
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US20030158195A1 (en) 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP2006522125A (ja) 2003-03-25 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
WO2006129100A1 (en) 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2061786A2 (en) 2006-09-07 2009-05-27 Biogen Idec MA Inc. Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
KR101566840B1 (ko) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2009026107A1 (en) 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
SG165655A1 (en) 2008-04-16 2010-11-29 Portola Pharm Inc 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
HRP20161310T1 (hr) 2008-04-16 2016-12-02 Portola Pharmaceuticals, Inc. 2,6-diamino-pirimidin-5-il-karboksamidi kao inhibitori syk ili jak kinaza
PL2716157T3 (pl) 2008-12-08 2017-06-30 Gilead Connecticut, Inc. Imidazopirazynowe inhibitory Syk
KR101445012B1 (ko) 2009-12-17 2014-09-26 머크 샤프 앤드 돔 코포레이션 Ｓｙｋ 억제제로서의 아미노피리미딘
NZ601267A (en) * 2009-12-23 2014-03-28 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
BR112013015460B1 (pt) 2010-12-20 2022-01-25 Merck Serono S.A. Derivados de indazolil triazol, kit, e composição farmacêutica
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
WO2015131080A1 (en) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
TN2017000080A1 (en) 2014-12-18 2018-07-04 Takeda Pharmaceuticals Co Solid state forms of fused heteroaromatic pyrrolidinones
TWI788655B (zh) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
MX394560B (es) 2016-06-01 2025-03-24 Bayer Pharma AG Uso de indazoles sustituidos para el tratamiento y la prevencion de enfermedades en animales.
US11174254B2 (en) * 2017-09-28 2021-11-16 Yangtze River Pharmaceutical Group Co., Ltd. Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof

Also Published As

Publication number Publication date
SG11202002475TA (en) 2020-04-29
KR20200073216A (ko) 2020-06-23
CL2020001036A1 (es) 2020-10-23
JP2020537678A (ja) 2020-12-24
CN111194319A (zh) 2020-05-22
DOP2020000093A (es) 2020-09-30
AU2018350683A1 (en) 2020-04-02
US11077111B2 (en) 2021-08-03
CA3079292A1 (en) 2019-04-25
TW201922744A (zh) 2019-06-16
UY37945A (es) 2019-05-31
EP3665171A1 (en) 2020-06-17
US20200261461A1 (en) 2020-08-20
BR112020007679A2 (pt) 2020-10-20
PH12020550444A1 (en) 2021-04-26
WO2019076817A1 (en) 2019-04-25
RU2020116178A (ru) 2021-11-19
IL273834A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
CR20150476A (es) Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares
ECSP18001308A (es) Derivados de oxopiridina sustituidos
PT3889145T (pt) 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários
CU20150095A7 (es) Pirimidinas fusionadas sustituidas con trifluorometilo
CL2017003404A1 (es) Compuestos antibacterianos
SV2018005775A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2- carboxamida
SI3464266T1 (sl) Substituirani indazoli, uporabni pri zdravljenju in preprečevanju alergijskih in/ali vnetnih bolezni pri živalih
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
CU24407B1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
CU20200041A7 (es) Amidas de imidazopiridina sustituidas
HRP20190013T1 (hr) Derivati 1,2-dihidro-3h-pirolo[1,2 -c]imidazol-3-ona i njihova uporaba kao antibakterijska sredstva
UY36373A (es) Compuestos para usarse en el tratamiento antihelmíntico
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
CO2019002361A2 (es) 1–arilnaftiridin–3–carboxamidas 7–sustituidas y su uso
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
DOP2020000093A (es) Uso de pirrolidonas heteroaromáticas fusionadas para el tratamiento y prevención de enfermedades en animales
EP3292872C0 (en) Composition for treatment or prevention of infectious inflammatory disease, or composition for immune enhancement, comprising tryptophanyl-trna synthetase as active ingredient
CR20150659A (es) Derivados de prodroga de triazolpiridinas sustituidas
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
SI3648761T1 (sl) Telmisartan za profilakso ali zdravljenje hipertenzije pri mačkah
MX375918B (es) Composiciones para el tratamiento de la fibrosis y afecciones relacionadas con la fibrosis.
CO2019011285A2 (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso
CR20150631A (es) Benzoxazoles sustituidos
CL2015003780A1 (es) Compuestos derivados pirimido-isoquinolin-quinonas, sus sales, isomeros, tautomeros farmacéuticas aceptables; composiciones farmáceuticas; procedimiento de preparación; y su uso en el tratamiento de enfermedades bacterianas y bacterianas multirresistentes.